CryoLife’s mission is to partner with clinicians to restore the health of patients by delivering innovative technologies of unsurpassed quality. CryoLife is one of the world’s leading contemporary medical device companies, providing preserved human tissues for cardiac and vascular surgeries, mechanical heart valves for aortic or mitral valve replacement, surgical adhesives and sealants, cardiac lasers for treatment of refractory angina, and state-of-the-art technology and surgical training in adult and pediatric cardiovascular surgery.
Since the company’s inception in 1984, it is estimated that CryoLife’s products and tissues have been implanted in over 1 million patients worldwide.
CryoLife is headquartered in Kennesaw, Georgia, 20 miles northwest of Atlanta, with offices in Austin, Texas and Guildford, Surrey, UK, as well as sales and marketing centers in Germany and Singapore, and representation in over 85 countries worldwide.
The firm’s 700 employees hail from 11 countries and speak 17 languages. CryoLife’s staff includes four full-time physicians and seven Ph.D.s, with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry.
CryoLife is a public company and is traded on the New York Stock Exchange under the symbol CRY.
We invite you to watch our Corporate Overview video.